Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Neutral 0

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

📉 Vertex Pharmaceuticals (VRTX) stock closed at $430.50, down 1.06% after the previous day's close.

🏛️ The S&P 500 gained 0.8%, while VRTX underperformed by missing both the broader index and its own monthly gains.

📅 The company is expected to release earnings on May 4, 2026, with analyst consensus EPS estimates of $4.2.

💰 Analysts project quarterly revenue of $2.98 billion, representing a 7.65% increase year-over-year.

📈 For the full annual period, expected EPS is $18.92 and revenue is $12.95 billion, with slight growth projections.

⚖️ VRTX currently carries a Zacks Rank of #3 (Hold), indicating neutral sentiment from analysts.

💵 The stock trades at a Forward P/E ratio of 22.99, which is slightly higher than the industry average of 21.28.

📊 The PEG ratio stands at 1.72, compared to an industry average of 1.49 for medical stocks.

🏥 VRTX belongs to a medical sector classified with a Zacks Industry Rank of 96, placing it in the top 40% of all industries.

🔮 Over the past month, consensus EPS estimates have decreased by 0.73%, potentially reflecting near-term business trends.

🎯 Research Director Sheraz Mian recently selected VRTX as a "single best pick," though no specific target was linked in the main article context.

🤖 The Zacks Rank system has historically averaged +23.89% annual returns since 1988 based on earnings estimate revisions.

📄 A free stock analysis report for Vertex Pharmaceuticals is available through Zacks Investment Research.

Bullish Signals
  • Vertex Pharmaceuticals is expected to report an EPS of $4.2 in the upcoming earnings release on May 4, 2026, marking a projected 3.45% year-over-year increase.
  • Consensus estimates anticipate quarterly revenue of $2.98 billion, representing a 7.65% growth from the year-ago period.
  • Annual consensus estimates project earnings of $18.92 per share and revenue of $12.95 billion, signifying growth of +2.83% and +7.86%, respectively.
  • Vertex Pharmaceuticals is currently carrying a Zacks Rank of #3 (Hold), which indicates a positive long-term outlook from analysts.
Risk Factors
  • Vertex Pharmaceuticals stock fell 1.06% on the day, underperforming the S&P 500 which gained 0.8% and trailing significantly behind the Nasdaq's 1.63% increase.
  • The stock has declined 4.11% over the previous month, performing worse than both the Medical sector and the broader market despite positive earnings expectations.
  • Analyst estimates for Vertex Pharmaceuticals have recently moved 0.73% lower, which correlates with recent stock price weakness according to Zacks research.
  • Vertex is currently assigned a Zacks Rank of #3 (Hold), indicating the company does not meet the criteria for a Strong Buy (#1) or even an Outperform rating.
  • The company trades at a Forward P/E ratio of 22.99, which is valued at a premium compared to its industry average of 21.28.
  • The stock's PEG ratio of 1.72 exceeds the industry average of 1.49 for Medical - Biomedical and Genetics stocks, suggesting potential overvaluation relative to expected earnings growth.
Full Analysis
Vertex Pharmaceuticals (VRTX) shares declined 1.06% to close at $430.50, underperforming the broader market as the S&P 500 rose 0.8% and the Nasdaq gained 1.63%. Over the previous month, VRTX lost 4.11%, trailing the Medical sector's slight loss of 0.32% while significantly lagging the S&P 500's monthly gain of 8.11%. The recent stock dip occurred amidst upcoming earnings expectations for May 4, 2026, with analysts projecting an EPS of $4.2—a 3.45% year-over-year increase—and quarterly revenue of $2.98 billion, representing a 7.65% rise from the prior year period. Annual consensus estimates anticipate earnings of $18.92 per share and revenue of $12.95 billion, with projected growth of +2.83% and +7.86%, respectively. Valuation metrics indicate Vertex is trading at a Forward P/E ratio of 22.99, which commands a premium compared to its industry average Forward P/E of 21.28. The company's PEG ratio stands at 1.72, slightly higher than the peer average of 1.49 for Medical - Biomedical and Genetics stocks. In terms of analyst ratings, Vertex holds a Zacks Rank of #3 (Hold), following a recent downward adjustment of 0.73% to its consensus EPS estimate. The medical industry as a whole maintains a Zacks Industry Rank of 96, positioning it within the top 40% of all tracked industries, which research suggests tends to outperform lower-rated sectors by a factor of two to one.